An isolated bioactive peptide-bearing antibody, or antigen-binding fragment thereof, comprising: (i) a heavy chain variable region and a light chain variable region each comprising three CDRs that specifically bind to human MASP-2, set forth as SEQ ID NO:4, wherein said heavy chain variable region comprises SEQ ID NO: 111 and said light chain variable region comprises SEQ ID NO: 115; and (ii) an SGMI peptide sequence set forth as SEQ ID NO:6 or SEQ ID NO 9, (a) wherein the SGMI peptide sequence comprising SGMI-1 set forth as SEQ ID NO:6 is fused to the amino terminal region of the heavy chain variable region of the antibody; (b) wherein the SGMI peptide sequence comprising SGMI-1 set forth as SEQ ID NO:6 is fused to the amino terminal region of the light chain variable region of the antibody; (c) wherein the SGMI peptide sequence comprising SGMI-1 set forth as SEQ ID NO:6 is fused to the carboxy terminal region of the light chain constant region of the antibody; (d) wherein the SGMI peptide sequence comprising SGMI-2 set forth as SEQ ID NO:9 is fused to the carboxy terminal region of the heavy chain constant region of the antibody; (e) wherein the SGMI peptide sequence comprising SGMI-2 set forth as SEQ ID NO:9 is fused to the amino terminal region of the light chain variable region of the antibody; and (f) wherein the SGMI peptide sequence comprising SGMI-2 set forth as SEQ ID NO:9 is fused to the carboxy terminal region of the light chain constant region of the antibody. (i) a heavy chain variable region and a light chain variable region each comprising three CDRs that specifically bind to human MASP-2, set forth as SEQ ID NO:4, wherein said heavy chain variable region comprises SEQ ID NO: 111 and said light chain variable region comprises SEQ ID NO: 115; and (ii) an SGMI peptide sequence set forth as SEQ ID NO:6 or SEQ ID NO 9, (a) wherein the SGMI peptide sequence comprising SGMI-1 set forth as SEQ ID NO:6 is fused to the amino terminal region of the heavy chain variable region of the antibody; (b) wherein the SGMI peptide sequence comprising SGMI-1 set forth as SEQ ID NO:6 is fused to the amino terminal region of the light chain variable region of the antibody; (c) wherein the SGMI peptide sequence comprising SGMI-1 set forth as SEQ ID NO:6 is fused to the carboxy terminal region of the light chain constant region of the antibody; (d) wherein the SGMI peptide sequence comprising SGMI-2 set forth as SEQ ID NO:9 is fused to the carboxy terminal region of the heavy chain constant region of the antibody; (e) wherein the SGMI peptide sequence comprising SGMI-2 set forth as SEQ ID NO:9 is fused to the amino terminal region of the light chain variable region of the antibody; and (f) wherein the SGMI peptide sequence comprising SGMI-2 set forth as SEQ ID NO:9 is fused to the carboxy terminal region of the light chain constant region of the antibody. (a) wherein the SGMI peptide sequence comprising SGMI-1 set forth as SEQ ID NO:6 is fused to the amino terminal region of the heavy chain variable region of the antibody; (b) wherein the SGMI peptide sequence comprising SGMI-1 set forth as SEQ ID NO:6 is fused to the amino terminal region of the light chain variable region of the antibody; (c) wherein the SGMI peptide sequence comprising SGMI-1 set forth as SEQ ID NO:6 is fused to the carboxy terminal region of the light chain constant region of the antibody; (d) wherein the SGMI peptide sequence comprising SGMI-2 set forth as SEQ ID NO:9 is fused to the carboxy terminal region of the heavy chain constant region of the antibody; (e) wherein the SGMI peptide sequence comprising SGMI-2 set forth as SEQ ID NO:9 is fused to the amino terminal region of the light chain variable region of the antibody; and (f) wherein the SGMI peptide sequence comprising SGMI-2 set forth as SEQ ID NO:9 is fused to the carboxy terminal region of the light chain constant region of the antibody. <EOS>